Multispecific binding proteins targeting CAIX, ANO1, mesothelin,TROP2, or claudin-18.2

A technology of connexin and cortex, applied in the direction of immunoglobulin, hybrid immunoglobulin, anti-enzyme immunoglobulin, etc.

Pending Publication Date: 2021-04-16
DRAGONFLY THERAPEUTICS INC
View PDF14 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Other types of cancer also remain challengi

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Multispecific binding proteins targeting CAIX, ANO1, mesothelin,TROP2, or claudin-18.2
  • Multispecific binding proteins targeting CAIX, ANO1, mesothelin,TROP2, or claudin-18.2
  • Multispecific binding proteins targeting CAIX, ANO1, mesothelin,TROP2, or claudin-18.2

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0260] Example 1 - NKG2D binding domains bind to NKG2D

[0261] NKG2D binding domain binds to purified recombinant NKG2D

[0262] The nucleic acid sequence of human, mouse or cynomolgus NKG2DNKG2D extracellular domains (ectodomains) is fused with the nucleic acid sequence encoding human IgG1 Fc domain, and introduced into mammalian cells for expression. After purification, the NKG2D-Fc fusion protein was adsorbed to the wells of a microplate. After blocking the wells with bovine serum albumin to prevent non-specific binding, the NKG2D binding domain was titrated and added to the wells pre-adsorbed with NKG2D-Fc fusion protein. Primary antibody binding was detected using a secondary antibody conjugated to horseradish peroxidase and specifically recognizing human kappa light chain to avoid Fc cross-reactivity. The substrate for horseradish peroxidase, 3,3',5,5'-tetramethylbenzidine (TMB), was added to the wells to visualize the binding signal, measured at 450 nm and correcte...

Embodiment 2

[0267] Example 2 - NKG2D Binding Domains Block Natural Ligand Binding to NKG2D

[0268] Competition with ULBP-6

[0269] The recombinant human NKG2D-Fc protein was adsorbed to the wells of a microplate, and the wells were blocked with bovine serum albumin to reduce non-specific binding. Saturating concentrations of ULBP-6-His-biotin were added to the wells, followed by NKG2D binding domain clones. After 2 hours of incubation, wells were washed and ULBP-6-His-biotin still bound to NKG2D-Fc-coated wells was detected by streptavidin-coupled horseradish peroxidase and TMB substrate. Absorbance was measured at 450nm and corrected at 540nm. The specific binding of the NKG2D binding domain to the NKG2D-Fc protein was calculated from the percentage of ULBP-6-His-biotin blocked from binding to the NKG2D-Fc protein in the wells after background subtraction. Positive control antibodies (selected from SEQ ID NO: 47-50) and various NKG2D binding domains blocked ULBP-6 binding to NKG2D...

Embodiment 3

[0276] Example 3 - NKG2D binding domain cloning activates NKG2D

[0277] The nucleic acid sequences of human and mouse NKG2D were fused to the nucleic acid sequence encoding the CD3ζ signaling domain to obtain chimeric antigen receptor (CAR) constructs. The NKG2D-CAR construct was then cloned into a retroviral vector using Gibson assembly and transfected into expi293 cells for retroviral production. EL4 cells were infected with NKG2D-CAR-containing virus together with 8 μg / mL polybrene. 24 hours after infection, the expression level of NKG2D-CAR in the EL4 cells was analyzed by flow cytometry, and clones expressing high levels of NKG2D-CAR on the cell surface were selected.

[0278] To determine whether NKG2D-binding domains activate NKG2D, they were adsorbed to wells of microplates and NKG2D-CAR EL4 cells were incubated on antibody fragment-coated wells in the presence of brefeldin-A and monensin Incubate for 4 hours. Intracellular TNF-[alpha] production, an indicator of N...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention relates to multispecific binding proteins targeting CAIX, ANO1, mesothelin, TROP2, or a claudin-18.2. In particular. Specifically, the present invention describes multispecific binding proteins that bind to the NKG2D receptor, CD16 and a tumor-associated antigen selected from the group consisting of carbonic anhydrase 9 (CAIX), calcitonin 1 (ANO1), mesothelin, TROP2, CEA and claudin-18.2, as well as pharmaceutical compositions and methods of treatment useful in the treatment of cancer.

Description

[0001] This application is a divisional application of the Chinese invention patent application with the application date of February 27, 2018, the application number 201880028256.X, and the invention title as above. [0002] Cross References to Related Applications [0003] This application claims U.S. Application No. 62 / 464,341, filed February 27, 2017, U.S. Application No. 62 / 464,344, filed February 27, 2017, U.S. Application No. 62 / 464,347, filed February 27, 2017, 2017 Benefit and Priority of U.S. Application No. 62 / 467,557, filed March 06, U.S. Application No. 62 / 473,652, filed March 20, 2017, and U.S. Application No. 62 / 473,659, filed March 20, 2017, the The entire content of each application is hereby incorporated by reference in its entirety for all purposes. [0004] sequence listing [0005] This application contains a Sequence Listing electronically filed in ASCII format and incorporated herein by reference in its entirety. The ASCII copy generated on February 27,...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C07K16/46A61K39/395A61P35/00
CPCA61P35/00C07K16/2851C07K16/30C07K16/3007C07K16/40C07K2317/31C07K2317/55C07K2317/60C07K2317/73C07K2317/92C07K2317/94C07K16/283C07K16/2803C07K2317/33C07K2317/75C07K16/28C07K16/46C07K16/18C07K2317/524C07K2317/565C07K2317/569C07K2317/76C07K2317/53
Inventor 格雷戈里·P·常安·F·张伊娃·古铁雷斯威廉·哈尼布拉德利·M·伦德比昂卡·普林茨
Owner DRAGONFLY THERAPEUTICS INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products